查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1834173

药物滥用检测市场（按样本类型、检测技术、最终用户和药物小组划分）—2025-2032 年全球预测

Drug of Abuse Testing Market by Sample Type, Test Technology, End User, Drug Panel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，药物滥用检测市场规模将成长至 33.4 亿美元，复合年增长率为 7.49%。

主要市场统计数据
基准年2024年 18.7亿美元
预计2025年 20.1亿美元
预测年份：2032年 33.4亿美元
复合年增长率（%） 7.49%

对当前药物滥用检测环境的权威说明，重点介绍不断变化的使用模式、跨部门需求和实际操作挑战

药物滥用检测是临床实践、法医学、公共卫生监测和职场安全的交叉领域。过去十年，物质的多样化、使用模式的改变以及监管审查的加强，迫使实验室和采购团队采用更准确、更快速、更全面的分析方法。同时，最终用户越来越需要能够在诊断准确性、週转时间和成本效益之间取得平衡的解决方案，这迫使技术供应商在检测方法、仪器和数据管理方面不断创新。

随着相关人员的不断适应，生态系统正在从传统的医院和法医学环境扩展到惩教机构、职业健康服务提供者和以地区为基础筛检计画。这种多样化影响着检体类型、检测试剂盒以及筛检和确认方法的相对组合。因此，实验室必须重新思考工作流程设计、品质保证和供应链弹性，而监管机构也必须更新其框架，以应对新兴合成药物和新型精神活性物质。在此背景下，对于寻求使能力与不断变化的需求模式和合规期望保持一致的领导者来说，了解样本采集选择、分析平台和最终用户需求之间的相互关係至关重要。

技术创新、多样化的样本应用和数位整合如何重塑测试的分析方法和相关人员的期望

由于分析化学的进步、对照护现场和快速确认工作流程的需求不断增长，以及标靶药物组合类型的扩展，滥用药物检测领域正在发生重大变化。高解析度和串联式质谱质谱仪已从专业参考实验室迁移到更广泛的临床和法医学环境中，从而能够更可靠地检测低浓度代谢物和新型合成化合物。同时，免疫测量平台仍然是经济高效的筛检工具，但现在通常采用混合工作流程，其中层析法确认补充初步筛检并减少假阳性和假阴性。

同时，样本类型的创新正在改变下游物流和检测视窗。头髮分析为回顾性调查提供了长期暴露的宝贵见解，而口腔液体分析则提供了一种侵入性较小的现场替代方法，与近期使用情况密切相关。尿液检查由于其既定的方案和广泛的检验历史，仍然是许多计画的支柱。实验室资讯管理系统和连接解决方案简化了结果报告，支援监管链要求，并与电子健康记录和惩教管理系统整合。随着政策框架不断发展以适应新物质和隐私考虑，相关人员必须在技术机会与道德、法律和营运约束之间取得平衡，以确保采用这些技术能够增强分析的严谨性和相关人员的信任。

评估近期美国关税对实验室和供应商采购、供应链弹性和业务连续性的影响

美国近期的关税措施和贸易调整对药物滥用检测供应链产生了切实的影响，尤其对依赖国际采购设备、耗材和试剂的实验室和供应商而言。进口关税的提高导致层析法系统、质谱仪和专用耗材的到岸成本上升，迫使采购团队重新评估供应商合约、维护协议和总拥有成本的计算。这促使一些机构加快库存规划，并考虑对关键试剂进行策略性储备，以维持高通量检测环境的连续性。

此外，关税政策也鼓励供应商实现产品组合多元化和在地采购策略。为了降低买家的成本敏感性，仪器製造商和试剂供应商正在评估各种方案，例如重新配置生产布局、调整零件采购以及提供更灵活的租赁和服务模式。这种转变将对维修週期、保固范围和技术支援管道产生下游影响，尤其对于偏远和服务欠缺地区的机构。重要的是，面对成本动态，合规义务不会放鬆。实验室必须持续满足验证和认证标准，这可能会使快速更换供应商变得复杂。因此，决策者应优先考虑供应链透明度、合约保障措施和紧急时应对计画，以维护分析的完整性，同时应对关税主导的市场动态引起的成本波动。

以细分市场主导的观点，揭示样本类型、分析平台、最终用户需求和麵板配置如何相互作用，从而影响操作选择

细分市场层面的动态揭示了需求驱动因素和技术要求，这些因素因样本类型、分析技术、最终用户和样本组配置而异。就样本类型而言，头髮分析适用于回顾性暴露评估，并且往往更倾向于法医学和矫正应用，因为这些应用优先考虑更宽的检测视窗。另一方面，口腔液分析适用于即时筛检，这种筛检需要微创采集并与近期摄取量进行关联。尿液检查由于其标准化的流程以及在职业和临床环境中的广泛接受，在临床实验室和医院中保持主导地位。

从检测技术来看，免疫测量因其操作简单、单次检测成本低而仍适用于高性能筛检，而层析法法则对于某些确认性工作流程至关重要。在层析法中，气相层析质谱法 (GC-MS) 可对挥发性和热稳定性化合物进行可靠的分析，而液相层析法质谱法 (LC-MS) 已成为层析法广泛分析的首选方法，包括极性和热不稳定化合物。此外，液相层析法法本身又分为串联式质谱质谱配置（可实现标靶定量）和 LC-QToF 平台（可实现新型化合物的高解析度筛检和非标靶发现）。临床实验室和医院优先考虑通量、认证以及与患者记录的整合；法医学实验室优先考虑证据保管炼和法律情况下的可辩护性；惩教机构更倾向于稳健且易于管理的工作流程；专业实验室可能需要可自订的检测菜单。最后，药物小组的组成决定了采购和营运规划。客製化的扩展面板可满足复杂的临床研究和法医学调查的需求，而固定的 5 和 10 面板选项则平衡了整体性和成本效益，可满足许多日常职场和路边筛检要求。

将监管、基础设施和渗透因素与全球市场的不同发展和采用路径联繫起来的区域分析

区域差异反映了管理体制、医疗保健基础设施成熟度和采用模式，这些因素共同塑造了采用路径和服务交付模式。在美洲，刑事鑑定和职场检测框架相对成熟，支援强大的参考实验室网路、多样化的检测组合以及整合的报告基础设施。随着相关人员响应公共卫生倡议和雇主主导的合规计划，对高性能仪器和监管链系统的投资仍然是优先事项。

在欧洲、中东和非洲，监管协调工作与巨大的国家和地区差异并存，导致先进仪器和确认性检测实践的采用曲线各不相同。一些市场强调严格的认证和法律倡导，而其他市场则支持对层析法确认性检测的需求，还有一些市场优先考虑可在分散的医疗保健系统中部署的可扩展筛检解决方案。在亚太地区，临床和刑事鑑定实验室的快速现代化，加上公共卫生监测的不断扩大，正在推动人们对高解析度质谱和分散式样本采集策略的兴趣。该地区还提供了本地化供应链和开发服务模式的机会，以满足都市区地区不同的物流和培训需求。在整个地区，互通性、劳动力能力和监管一致性仍然是扩展可靠检测服务的关键推动因素。

考虑决定公司如何获得价值的竞争优势和服务差异化，包括仪器可靠性、分析深度和数位化准备度

在分析平台日益复杂的时代，竞争动态强调整合服务、可靠的售后支援和协作研究伙伴关係。领先的仪器製造商在分析性能、使用者介面设计和认证耗材生态系统方面展开竞争，这些生态系统旨在减少差异性并简化验证。对于那些面临人员限制且需要可预测正常执行时间以实现高通量操作的实验室来说，能够提供完善的培训、快速响应的技术支援和灵活服务协议的供应商正日益受到青睐。

与此同时，诊断和检测服务供应商正透过专业的检测方法开发、可自订的试剂盒配置以及针对临床、法医学和矫正用例的快速交付来脱颖而出。仪器供应商和检测方法开发商之间的开发合作正在促成捆绑解决方案，从而降低采用先进方法的门槛。此外，提供实验室资讯管理、结果解读支援以及与医疗保健系统连接的软体和资讯学公司正透过提高工作流程效率和确保符合报告标准发挥日益重要的战略作用。总体而言，那些将卓越的仪器与生命週期支援、检测深度和数位化赋能相结合的公司，最有能力满足不同最终用户不断变化的需求。

产业领导者可采取的策略重点，以加强测试可靠性、供应弹性、劳动力和监管参与

药物滥用检测生态系统的领导者应优先考虑三项并行行动，以增强韧性并抓住新机会。首先，投资模组化混合检测架构，该架构将免疫测量筛检与层析法确认相结合，并融合集中式和分散式样品工作流程。这种方法使组织能够优化成本和交付时间，同时保持法医学和临床应用的分析防御能力。其次，透过多元化供应商关係、协商延长支援期以及建立关键耗材的紧急库存，提高供应链透明度和合约弹性。这些措施可以减少进口关税波动和物流中断带来的风险。

第三，我们将透过投资实验室资讯学和有针对性的培训计画来提升员工能力和数位化水平，从而简化报告、品管和法规遵循流程。加强技术能力和数据工作流程将使各机构能够扩展先进的检测模式，并将其整合到更广泛的临床和公共卫生计划中。最后，我们将积极与政策制定者和标准组织合作，针对新兴物质和新型样本类型製定实用的、循证的指南。这些综合行动将在不断变化的政策和技术环境中，为营运稳定性、卓越的分析能力和灵活的商业策略奠定基础。

透明、多方法的调查方法结合了相关人员访谈、技术检验证据和监管审查，支持可行的建议

本执行摘要所依据的研究结合了对实验室主任、采购经理和法医学专家的初步访谈，以及对近期同行评审文献、监管指南和公共卫生监测报告的二次分析。调查方法的严谨性源自于将定性洞察与透过多项独立检验研究记录的检测技术和仪器性能属性进行三角检验。我们还审查了案例研究和供应商能力评估，以确定反覆出现的营运主题，例如工作流程整合、维护模型和培训需求。

在整个分析过程中，我们特别注重确保可重复性和透明度。证据的权重由来源类型和研究纳入标准决定，敏感性检查则用于处理供应商提供的资讯可能造成的偏倚。当监管解释有争议时，评估依据公开的政策文件和专业协会的共识声明。这种混合方法有助于得出平衡的结论，同时考虑临床环境的异质性和技术变革的步伐。

最后综合总结了综合技术采用、供应链规划和劳动力发展将如何决定未来检查的可靠性和影响力。

总而言之，药物滥用检测领域正处于关键时刻，技术能力、政策转变和最终用户的多样性正在汇聚，重新定义操作规范。实验室和供应商既面临着整合复杂分析平台的挑战，也面临着提供更可靠结果以更好地服务临床护理、法医学流程和公共的机会。供应链压力和不断变化的贸易政策要求我们制定积极的采购和应急计划，而地区差异则要求我们制定因地制宜的部署策略。

展望未来，那些采用混合检测模式、投资于员工团队建设和数位化工作流程，并在整个价值链上建立合作伙伴关係关係的组织将获得成功。透过将技术投资与样本类型、最终用户需求和监管期望等实际因素相结合，相关人员可以提高检测的可靠性，并确保结果在临床、法律和专业领域具有可操作性。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 临床环境中越来越多地采用灵敏质谱法进行全面的药物筛检
  • 扩大分散式口腔液体即时检测，以便在偏远地区快速检测合成鸦片类药物
  • 将人工智慧驱动的预测分析整合到您的实验室中，以解释药物代谢物并减少假阳性
  • SAMHSA 认证合规监管压力不断加大，推动标准化尿液免疫检测面板的采用
  • 家用多功能检测套组的普及使得雇主能够远端进行筛检前和持续的筛检。
  • 开发多重 LC-MS/MS 分析方法，用于同时定量新型合成大麻素和鸦片类药物
  • 加强远端医疗提供者和临床实验室之间的合作，以促进远距药物测试和监测项目
  • 在法医学和临床应用中，对毛囊分析以检测长期药物使用模式的需求日益增长。

第六章 2025年美国关税的累积影响

第七章 人工智慧的累积影响，2025年

8. 药物滥用检测市场（依样本类型）

  • 头髮
  • 口腔液体
  • 尿

9. 药物滥用检测市场（依检测技术）

  • 层析法
    • GC-MS
    • Lc-Ms
      • Lc-Ms/Ms
      • Lc-Qtof
  • 免疫检测

第 10 章。药物滥用检测市场（按最终用户）

  • 临床实验室
  • 惩教设施
  • 法医学实验室
  • 医院

第 11 章。药物滥用检测市场（按药物小组）

  • 可自订面板
  • 放大面板
  • 5个面板
  • 10个面板

12. 药物滥用检测市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章药物滥用检测市场（按类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国滥用药物检测市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Thermo Fisher Scientific Inc.
    • Roche Holding AG
    • Abbott Laboratories
    • Siemens Healthineers AG
    • Danaher Corporation
    • Bio-Rad Laboratories, Inc.
    • Hologic, Inc.
    • PerkinElmer, Inc.
    • Sysmex Corporation
    • Becton, Dickinson and Company
Product Code: MRR-4348D129FA91

The Drug of Abuse Testing Market is projected to grow by USD 3.34 billion at a CAGR of 7.49% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.87 billion
Estimated Year [2025] USD 2.01 billion
Forecast Year [2032] USD 3.34 billion
CAGR (%) 7.49%

An authoritative orientation to the current drug of abuse testing environment highlighting evolving use patterns, cross-sector demands, and practical operational challenges

Drug of abuse testing sits at the intersection of clinical practice, forensic science, public health surveillance, and workplace safety. Over the past decade, escalating substance diversity, shifting patterns of use, and intensified regulatory scrutiny have placed testing laboratories and procurement teams under pressure to adopt more precise, rapid, and comprehensive analytical approaches. Meanwhile, end users increasingly demand solutions that balance diagnostic accuracy, turnaround time, and cost-efficiency, compelling technology providers to innovate across assay formats, instrumentation, and data management.

As stakeholders adapt, the ecosystem has expanded beyond traditional hospital and forensic settings to include correctional facilities, occupational health providers, and community-based screening programs. This diversification has implications for sample types, testing panels, and the relative mix of screening versus confirmatory methods. Consequently, laboratories must reconsider workflow design, quality assurance, and supply chain resilience while regulators update frameworks to address emerging synthetic drugs and novel psychoactive substances. In this context, understanding the interplay among sample collection choices, analytical platforms, and end-user requirements is essential for leaders aiming to align capabilities with evolving demand patterns and compliance expectations.

How technological breakthroughs, diversified sample applications, and digital integration are reshaping analytical approaches and stakeholder expectations in testing

The landscape of drug of abuse testing is undergoing transformative shifts driven by advancements in analytical chemistry, growing demand for point-of-care and rapid-confirmation workflows, and an expanding palette of targeted drug panels. High-resolution mass spectrometry and tandem mass spectrometry have migrated from specialized reference laboratories into broader clinical and forensic settings, enabling detection of low-concentration metabolites and emerging synthetic compounds with greater confidence. At the same time, immunoassay platforms continue to serve as cost-effective screening tools, but they now frequently operate in hybrid workflows where chromatographic confirmation complements initial screening to mitigate false positives and negatives.

Concurrently, sample-type innovation is changing downstream logistics and detection windows. Hair analysis offers long-term exposure insights that are valuable for retrospective investigations, while oral fluid presents a less invasive, on-site alternative that correlates well with recent use. Urine testing remains the backbone of many programs due to established protocols and extensive validation histories. These shifts also intersect with digital transformation: laboratory information management systems and connectivity solutions streamline result reporting, support chain-of-custody requirements, and integrate with electronic health records and corrections management systems. As policy frameworks evolve to address novel substances and privacy considerations, stakeholders must balance technological opportunity with ethical, legal, and operational constraints, ensuring that adoption enhances both analytical rigor and stakeholder trust.

Assessing how recent United States tariff measures are influencing procurement, supply chain resilience, and operational continuity for laboratories and vendors

Recent tariff actions and trade policy recalibrations in the United States are creating tangible implications for the drug of abuse testing supply chain, particularly for laboratories and vendors that rely on internationally sourced instrumentation, consumables, and reagents. Increased import duties elevate landed costs for chromatography systems, mass spectrometers, and specialized disposables, prompting procurement teams to reassess vendor agreements, maintenance contracts, and total cost of ownership calculations. In response, some organizations are accelerating inventory planning and exploring strategic stockpiling of critical reagents to maintain continuity in high-throughput testing environments.

Moreover, the tariffs are encouraging diversification of supplier portfolios and localized sourcing strategies. Instrument manufacturers and reagent suppliers are evaluating options to reconfigure manufacturing footprints, adjust component sourcing, or offer more flexible leasing and service models to mitigate buyer cost sensitivity. This shift has downstream effects on maintenance turnarounds, warranty coverage, and technical support channels, especially for facilities in remote or underserved regions. Importantly, regulatory compliance obligations do not relax in the face of cost pressures; laboratories must continue to satisfy validation and accreditation standards, which can complicate rapid vendor switching. Therefore, decision-makers should prioritize supply chain transparency, contractual safeguards, and contingency planning to preserve analytical integrity while managing cost volatility induced by tariff-driven market dynamics.

Segment-driven perspectives illuminating how sample types, analytical platforms, end-user requirements, and panel composition interact to shape operational choices

Segment-level dynamics reveal differentiated demand drivers and technical requirements across sample types, analytical technologies, end users, and panel configurations. When considering sample type, hair analysis caters to retrospective exposure assessment and tends to attract forensic and correctional use cases that prioritize extended detection windows, while oral fluid appeals to on-site screening contexts that require minimally invasive collection and correlation with recent consumption. Urine testing maintains prominence across clinical laboratories and hospitals because of standardized procedures and broad acceptance in occupational and clinical settings.

Turning to test technology, immunoassay methods retain relevance for high-throughput screening due to their operational simplicity and lower per-test cost, yet chromatography-based approaches are essential for specific confirmation workflows. Within chromatography, gas chromatography-mass spectrometry provides reliable analysis for volatile and thermally stable compounds, whereas liquid chromatography-mass spectrometry has emerged as the preferred modality for a broader array of polar and thermally labile analytes. Moreover, the liquid chromatography category itself bifurcates into tandem mass spectrometry configurations that deliver targeted quantitation and LC-QToF platforms that enable high-resolution screening and untargeted discovery of novel compounds. End-user segmentation also influences technology choices and service models: clinical laboratories and hospitals emphasize throughput, accreditation, and integration with patient records; forensic labs prioritize chain-of-custody and defensibility in legal contexts; correctional facilities favor rugged, easy-to-administer workflows; and specialized laboratories may require customizable testing menus. Finally, drug panel configuration shapes procurement and operational planning: customized and expanded panels meet the needs of complex clinical and forensic investigations, while fixed five- and ten-panel options address many routine workplace and roadside screening requirements, balancing comprehensiveness with cost-effectiveness.

A regional analysis that connects regulatory, infrastructural, and prevalence factors to differentiated deployment and adoption pathways across global markets

Regional differentiation reflects regulatory regimes, healthcare infrastructure maturity, and prevalence patterns that collectively shape adoption pathways and service delivery models. In the Americas, forensic and workplace testing frameworks are relatively mature, supporting a robust network of reference laboratories, diversified assay portfolios, and integrated reporting infrastructures. Investment in high-throughput instrumentation and chain-of-custody systems remains a priority as stakeholders respond to both public health initiatives and employer-driven compliance programs.

In Europe, the Middle East, and Africa region, regulatory harmonization efforts coexist with significant heterogeneity across jurisdictions, producing varied adoption curves for advanced instrumentation and confirmatory testing practices. Some markets emphasize stringent accreditation and legal defensibility, which supports demand for chromatography-based confirmation, while others prioritize scalable screening solutions that can be deployed across fragmented healthcare systems. In the Asia-Pacific region, rapid modernization of clinical and forensic laboratories, coupled with expanding public health surveillance, is driving interest in both high-resolution mass spectrometry and decentralized sample collection strategies. This region also presents opportunities to localize supply chains and develop service models that address diverse logistical and training needs across urban and rural settings. Across all regions, interoperability, workforce competency, and regulatory alignment remain critical enablers for scaling reliable testing services.

Insights into competitive strengths and service differentiation that determine how companies capture value across instrument reliability, assay depth, and digital enablement

Competitive dynamics in the era of sophisticated analytical platforms place a premium on integrated service offerings, reliable post-sale support, and collaborative research partnerships. Leading instrument manufacturers compete on analytical performance, user interface design, and the ecosystem of certified consumables that reduce variability and simplify validation. Vendors that provide robust training, rapid technical support, and flexible service contracts gain traction among laboratories that face staffing constraints and need predictable uptime for high-throughput operations.

At the same time, diagnostic and laboratory services providers differentiate through specialized assay development, customizable panel configurations, and fast turnarounds tailored to clinical, forensic, and correctional use cases. Collaborations between instrument vendors and assay developers are enabling bundled solutions that lower barriers to adopting advanced methodologies. Additionally, software and informatics companies that offer laboratory information management, result interpretation aids, and connectivity to health systems play an increasingly strategic role by improving workflow efficiency and ensuring compliance with reporting standards. Overall, companies that combine instrument excellence with lifecycle support, assay depth, and digital enablement are best positioned to serve the evolving needs of diverse end users.

Actionable strategic priorities for industry leaders to enhance testing reliability, supply resilience, workforce capability, and regulatory engagement

Leaders in the drug of abuse testing ecosystem should prioritize three parallel actions to strengthen resilience and capture emerging opportunities. First, invest in modular, hybrid testing architectures that combine immunoassay screening with chromatography-based confirmation and incorporate both centralized and decentralized sample workflows. This approach allows organizations to optimize cost and turnaround time while maintaining analytical defensibility for forensic and clinical applications. Second, enhance supply chain transparency and contractual flexibility by diversifying supplier relationships, negotiating extended support terms, and building contingency inventories for critical consumables. Such measures mitigate exposure to import duty fluctuations and logistical disruptions.

Third, develop workforce capability and digital proficiency through targeted training programs and investments in laboratory informatics that streamline reporting, quality management, and regulatory compliance. By strengthening technical competencies and data workflows, organizations can scale advanced testing modalities and integrate them into broader clinical and public health initiatives. Finally, engage proactively with policymakers and standard-setting bodies to shape practical, evidence-based guidelines for emerging substances and novel sample types. Taken together, these actions create a foundation for operational stability, analytical excellence, and adaptive commercial strategies in a shifting policy and technological environment.

A transparent, multi-method research approach combining stakeholder interviews, technical validation evidence, and regulatory review to underpin practical recommendations

The research underpinning this executive summary synthesizes primary interviews with laboratory directors, procurement managers, and forensic specialists together with secondary analysis of recent peer-reviewed literature, regulatory guidance, and public health surveillance reports. Methodological rigor derives from triangulating qualitative insights with documented performance attributes of assay technologies and instrumentation across multiple independent validation studies. Case examples and vendor capability assessments were reviewed to identify recurring operational themes, such as workflow integration, maintenance models, and training needs.

Throughout the analysis, particular attention was paid to ensuring reproducibility and transparency: source types and study selection criteria guided evidence weighting, and sensitivity checks addressed potential biases stemming from vendor-provided information. Where regulatory interpretations were discussed, the assessment relied on publicly available policy documents and consensus statements from professional societies. This blended approach supports balanced conclusions while acknowledging the heterogeneity of practice environments and the pace of technological change.

Concluding synthesis on how integrated technological adoption, supply chain planning, and workforce development will determine future testing reliability and impact

In summary, the drug of abuse testing domain is at a pivotal moment where technological capability, policy shifts, and end-user diversity converge to redefine operational norms. Laboratories and vendors face both the challenge of integrating sophisticated analytical platforms and the opportunity to deliver higher-confidence results that better serve clinical care, forensic processes, and public safety. Supply chain pressures and changing trade policies require proactive procurement and contingency planning, while regional differences demand context-sensitive deployment strategies.

Moving forward, success will favor organizations that adopt hybrid testing models, invest in workforce development and digital workflows, and build collaborative partnerships across the value chain. By aligning technological investments with practical considerations around sample types, end-user needs, and regulatory expectations, stakeholders can enhance testing reliability and ensure that results remain actionable in clinical, legal, and occupational contexts.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising adoption of high-sensitivity mass spectrometry for comprehensive drug screening in clinical settings
  • 5.2. Expansion of decentralized point-of-care oral fluid testing for rapid detection of synthetic opioids at remote sites
  • 5.3. Integration of AI-driven predictive analytics in laboratories to interpret drug metabolites and reduce false positives
  • 5.4. Growing regulatory pressure for SAMHSA certification compliance driving adoption of standardized urine immunoassay panels
  • 5.5. Surge in at-home multi-analyte test kits enabling employers to conduct remote pre-employment and ongoing screening
  • 5.6. Development of multiplexed LC-MS/MS assays for simultaneous quantification of emerging synthetic cannabinoids and opioids
  • 5.7. Increasing collaboration between telehealth providers and clinical labs to facilitate remote drug testing and monitoring programs
  • 5.8. Rising demand for hair follicle analysis to detect long-term substance use patterns in forensic and clinical applications

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Drug of Abuse Testing Market, by Sample Type

  • 8.1. Hair
  • 8.2. Oral Fluid
  • 8.3. Urine

9. Drug of Abuse Testing Market, by Test Technology

  • 9.1. Chromatography
    • 9.1.1. Gc-Ms
    • 9.1.2. Lc-Ms
      • 9.1.2.1. Lc-Ms/Ms
      • 9.1.2.2. Lc-Qtof
  • 9.2. Immunoassay

10. Drug of Abuse Testing Market, by End User

  • 10.1. Clinical Laboratory
  • 10.2. Correctional Facility
  • 10.3. Forensic Laboratory
  • 10.4. Hospital

11. Drug of Abuse Testing Market, by Drug Panel

  • 11.1. Customized Panel
  • 11.2. Expanded Panel
  • 11.3. Five Panel
  • 11.4. Ten Panel

12. Drug of Abuse Testing Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Drug of Abuse Testing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Drug of Abuse Testing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Thermo Fisher Scientific Inc.
    • 15.3.2. Roche Holding AG
    • 15.3.3. Abbott Laboratories
    • 15.3.4. Siemens Healthineers AG
    • 15.3.5. Danaher Corporation
    • 15.3.6. Bio-Rad Laboratories, Inc.
    • 15.3.7. Hologic, Inc.
    • 15.3.8. PerkinElmer, Inc.
    • 15.3.9. Sysmex Corporation
    • 15.3.10. Becton, Dickinson and Company

LIST OF FIGURES

  • FIGURE 1. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. DRUG OF ABUSE TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. DRUG OF ABUSE TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. DRUG OF ABUSE TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY HAIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY HAIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY HAIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY HAIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY HAIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY HAIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY ORAL FLUID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY ORAL FLUID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY ORAL FLUID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY ORAL FLUID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY ORAL FLUID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY ORAL FLUID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY URINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY URINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY URINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY URINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY URINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY URINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY GC-MS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY GC-MS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY GC-MS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY GC-MS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY GC-MS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY GC-MS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS/MS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS/MS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS/MS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS/MS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS/MS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS/MS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY LC-QTOF, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY LC-QTOF, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY LC-QTOF, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY LC-QTOF, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY LC-QTOF, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY LC-QTOF, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CLINICAL LABORATORY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CLINICAL LABORATORY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CLINICAL LABORATORY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CLINICAL LABORATORY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CLINICAL LABORATORY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CLINICAL LABORATORY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CORRECTIONAL FACILITY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CORRECTIONAL FACILITY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CORRECTIONAL FACILITY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CORRECTIONAL FACILITY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CORRECTIONAL FACILITY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CORRECTIONAL FACILITY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY FORENSIC LABORATORY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY FORENSIC LABORATORY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY FORENSIC LABORATORY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY FORENSIC LABORATORY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY FORENSIC LABORATORY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY FORENSIC LABORATORY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CUSTOMIZED PANEL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CUSTOMIZED PANEL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CUSTOMIZED PANEL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CUSTOMIZED PANEL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CUSTOMIZED PANEL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CUSTOMIZED PANEL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY EXPANDED PANEL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY EXPANDED PANEL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY EXPANDED PANEL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY EXPANDED PANEL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY EXPANDED PANEL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY EXPANDED PANEL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY FIVE PANEL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY FIVE PANEL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY FIVE PANEL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY FIVE PANEL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY FIVE PANEL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY FIVE PANEL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY TEN PANEL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY TEN PANEL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY TEN PANEL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY TEN PANEL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY TEN PANEL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY TEN PANEL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 122. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 123. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 124. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 125. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 126. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 127. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 128. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 129. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2024 (USD MILLION)
  • TABLE 130. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2025-2032 (USD MILLION)
  • TABLE 131. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 132. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 133. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2024 (USD MILLION)
  • TABLE 134. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2025-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. NORTH AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 138. NORTH AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 140. NORTH AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 142. NORTH AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2024 (USD MILLION)
  • TABLE 144. NORTH AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2025-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 146. NORTH AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2024 (USD MILLION)
  • TABLE 148. NORTH AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2025-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. LATIN AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 152. LATIN AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 154. LATIN AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 156. LATIN AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2024 (USD MILLION)
  • TABLE 158. LATIN AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2025-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 160. LATIN AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2024 (USD MILLION)
  • TABLE 162. LATIN AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2025-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2025-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPE DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2025-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. MIDDLE EAST DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. MIDDLE EAST DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 196. MIDDLE EAST DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 198. MIDDLE EAST DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2024 (USD MILLION)
  • TABLE 200. MIDDLE EAST DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2025-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. MIDDLE EAST DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2024 (USD MILLION)
  • TABLE 204. MIDDLE EAST DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2025-2032 (USD MILLION)
  • TABLE 205. AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 210. AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 211. AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 212. AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 213. AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2024 (USD MILLION)
  • TABLE 214. AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2025-2032 (USD MILLION)
  • TABLE 215. AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 216. AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 217. AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2024 (USD MILLION)
  • TABLE 218. AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2025-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2024 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2025-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2024 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. ASEAN DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. ASEAN DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. ASEAN DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. ASEAN DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. ASEAN DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 240. ASEAN DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 241. ASEAN DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 242. ASEAN DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 243. ASEAN DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2024 (USD MILLION)
  • TABLE 244. ASEAN DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2025-2032 (USD MILLION)
  • TABLE 245. ASEAN DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. ASEAN DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 247. ASEAN DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2024 (USD MILLION)
  • TABLE 248. ASEAN DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2025-2032 (USD MILLION)
  • TABLE 249. GCC DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GCC DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GCC DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. GCC DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 253. GCC DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 254. GCC DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 255. GCC DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 256. GCC DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 257. GCC DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2024 (USD MILLION)
  • TABLE 258. GCC DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2025-2032 (USD MILLION)
  • TABLE 259. GCC DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. GCC DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. GCC DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2024 (USD MILLION)
  • TABLE 262. GCC DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPEAN UNION DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPEAN UNION DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPEAN UNION DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPEAN UNION DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPEAN UNION DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPEAN UNION DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPEAN UNION DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2025-2032 (USD MILLION)
  • TABLE 277. BRICS DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. BRICS DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. BRICS DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. BRICS DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. BRICS DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 282. BRICS DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 283. BRICS DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 284. BRICS DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 285. BRICS DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2024 (USD MILLION)
  • TABLE 286. BRICS DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2025-2032 (USD MILLION)
  • TABLE 287. BRICS DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 288. BRICS DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 289. BRICS DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2024 (USD MILLION)
  • TABLE 290. BRICS DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2025-2032 (USD MILLION)
  • TABLE 291. G7 DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 292. G7 DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 293. G7 DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. G7 DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 295. G7 DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 296. G7 DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 297. G7 DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 298. G7 DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 299. G7 DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2024 (USD MILLION)
  • TABLE 300. G7 DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2025-2032 (USD MILLION)
  • TABLE 301. G7 DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 302. G7 DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 303. G7 DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2024 (USD MILLION)
  • TABLE 304. G7 DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2025-2032 (USD MILLION)
  • TABLE 305. NATO DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 306. NATO DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 307. NATO DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 308. NATO DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 309. NATO DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 310. NATO DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 311. NATO DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 312. NATO DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 313. NATO DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2024 (USD MILLION)
  • TABLE 314. NATO DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2025-2032 (USD MILLION)
  • TABLE 315. NATO DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 316. NATO DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 317. NATO DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2024 (USD MILLION)
  • TABLE 318. NATO DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2025-2032 (USD MILLION)
  • TABLE 319. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 320. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 321. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 322. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 323. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 324. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 325. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 326. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 327. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2024 (USD MILLION)
  • TABLE 328. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2025-2032 (USD MILLION)
  • TABLE 329. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 330. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 331. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2024 (USD MILLION)
  • TABLE 332. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2025-2032 (USD MILLION)
  • TABLE 333. CANADA DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 334. CANADA DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 335. CANADA DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 336. CANADA DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 337. CANADA DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)

TABLE 338.